US 12,313,624 B2
Ex vivo systems and methods for determining the effect of a drug or other agent on a tissue
Jonathan Daniel Oliner, Garrett Park, MD (US); Neil Anthony, Decatur, GA (US); Sean Caenepeel, Thousand Oaks, CA (US); Laura Catherine Funk Hrycyniak, Middleton, WI (US); John Rafter, Madison, WI (US); and Tomasz Zal, Madison, WI (US)
Assigned to Elephas Biosciences Corporation, Madison, WI (US)
Filed by Elephas Biosciences Corporation, Madison, WI (US)
Filed on Jun. 7, 2022, as Appl. No. 17/834,263.
Application 17/834,263 is a continuation of application No. 17/566,154, filed on Dec. 30, 2021, granted, now 11,366,101.
Claims priority of provisional application 63/236,282, filed on Aug. 24, 2021.
Claims priority of provisional application 63/132,725, filed on Dec. 31, 2020.
Prior Publication US 2022/0326220 A1, Oct. 13, 2022
Int. Cl. G06K 9/00 (2022.01); G01N 1/28 (2006.01); G01N 1/42 (2006.01); G01N 33/50 (2006.01); G01N 33/58 (2006.01); G06T 7/00 (2017.01)
CPC G01N 33/5011 (2013.01) [G01N 1/286 (2013.01); G01N 1/42 (2013.01); G01N 33/5014 (2013.01); G01N 33/582 (2013.01); G06T 7/0016 (2013.01); G01N 2001/2873 (2013.01); G06T 2207/10004 (2013.01); G06T 2207/10024 (2013.01); G06T 2207/10064 (2013.01); G06T 2207/30024 (2013.01); G06T 2207/30096 (2013.01)] 16 Claims
OG exemplary drawing
 
1. A method of predicting the clinical responsiveness of a subject to a potential anticancer drug or agent, the method comprising:
i. sorting tissue fragments containing or suspected of containing tumor cells into desirable fragments and undesirable fragments based on an optical characteristic, and dispensing a controlled number of desirable tissue fragments into chambers of a culture platform, wherein the tissue fragments are generated from a tissue obtained from a subject having or suspected of having cancer;
ii. adding a potential anticancer drug or agent to the desirable tissue fragments dispensed into the chambers of the culture platform and culturing the desirable tissue fragments in presence of the potential anticancer drug or agent;
iii. performing one or more ex-vivo measurements on the desirable tissue fragments; and
iv. predicting the clinical responsiveness of the subject to the potential anticancer drug or agent based on data obtained from the one or more ex-vivo measurements.